The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1284 participants.
Also called NCT01106677
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,284 participants
- Registry
-
NCT01106677
-
- Other papers using this trial's data
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Bulgaria, Colombia, Czechia, Estonia, Greece, India, Latvia, Malaysia, Mexico, Peru, Poland, Portugal, Puerto Rico, Russia, Singapore, Slovakia, Sweden, Thailand, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01106677. Randomized; triple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-10 (actual). Results posted on 2013-07-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Metformin immediate release
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01106677- Content hash
bf9fcdc768a802c67f2b4996673d2e2333f29290bd1b705ed5aa5e49763e27af